• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells.

作者信息

Greenberg P D

机构信息

Department of Medicine and Immunology, University of Washington, Seattle.

出版信息

Adv Immunol. 1991;49:281-355. doi: 10.1016/s0065-2776(08)60778-6.

DOI:10.1016/s0065-2776(08)60778-6
PMID:1853786
Abstract
摘要

相似文献

1
Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells.肿瘤的过继性T细胞疗法：在肿瘤细胞识别与清除中起作用的机制
Adv Immunol. 1991;49:281-355. doi: 10.1016/s0065-2776(08)60778-6.
2
Inhibition of early tumor growth requires J alpha 18-positive (natural killer T) cells.抑制肿瘤早期生长需要Jα18阳性（自然杀伤T）细胞。
Cancer Res. 2003 Jun 15;63(12):3058-60.
3
Strategies for immunotherapy of cancer.癌症免疫治疗策略。
Adv Immunol. 2000;75:235-82. doi: 10.1016/s0065-2776(00)75006-1.
4
Tumor eradication by adoptive transfer of cytotoxic T lymphocytes.通过细胞毒性T淋巴细胞的过继转移实现肿瘤根除。
Adv Cancer Res. 1992;58:143-75. doi: 10.1016/s0065-230x(08)60294-8.
5
Exploiting dendritic cells and natural killer T cells in immunotherapy against malignancies.在针对恶性肿瘤的免疫治疗中利用树突状细胞和自然杀伤T细胞。
Trends Immunol. 2008 May;29(5):242-9. doi: 10.1016/j.it.2008.02.002. Epub 2008 Mar 26.
6
Cytotoxic T lymphocyte therapy of cancer and tumor escape mechanisms.癌症的细胞毒性T淋巴细胞疗法与肿瘤逃逸机制
Semin Cancer Biol. 1991 Oct;2(5):347-54.
7
Strategies of lymphocyte activation for the adoptive immunotherapy of metastatic cancer: a review.用于转移性癌症过继性免疫治疗的淋巴细胞激活策略：综述
J Hematother. 1993 Spring;2(1):63-73. doi: 10.1089/scd.1.1993.2.63.
8
Immune modulation and safety profile of adoptive immunotherapy using expanded autologous activated lymphocytes against advanced cancer.采用扩增自体激活淋巴细胞过继免疫疗法治疗晚期癌症的免疫调节和安全性特征。
Clin Immunol. 2011 Jan;138(1):23-32. doi: 10.1016/j.clim.2010.08.012. Epub 2010 Oct 30.
9
Anti-tumour immunotherapy with Vγ9Vδ2 T lymphocytes: from the bench to the bedside.Vγ9Vδ2 T 淋巴细胞抗肿瘤免疫治疗：从基础到临床。
Br J Haematol. 2013 Jan;160(2):123-32. doi: 10.1111/bjh.12090. Epub 2012 Oct 15.
10
Tumor rejection antigens and tumor specific cytotoxic T lymphocytes.肿瘤排斥抗原与肿瘤特异性细胞毒性T淋巴细胞。
Behring Inst Mitt. 1994 Jul(94):72-86.

引用本文的文献

1
Bispecific antibody simultaneously targeting AGR2 and PD1 mediates cytotoxic T-cell-induced antitumor response in AGR2-dependent manner and inhibits AGR2-induced PDL1 upregulation.同时靶向AGR2和PD1的双特异性抗体以AGR2依赖性方式介导细胞毒性T细胞诱导的抗肿瘤反应，并抑制AGR2诱导的PDL1上调。
Sci Rep. 2025 Feb 19;15(1):6015. doi: 10.1038/s41598-025-88331-7.
2
Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors.肿瘤内免疫三联体是免疫治疗介导的实体瘤消除所必需的。
Cancer Cell. 2024 Jul 8;42(7):1202-1216.e8. doi: 10.1016/j.ccell.2024.05.025. Epub 2024 Jun 20.
3
HA-1-targeted T-cell receptor T-cell therapy for recurrent leukemia after hematopoietic stem cell transplantation.
HA-1 靶向 T 细胞受体 T 细胞疗法治疗造血干细胞移植后复发性白血病。
Blood. 2024 Sep 5;144(10):1069-1082. doi: 10.1182/blood.2024024105.
4
Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments.利用 CAR-T 细胞疗法的潜力：血液系统恶性肿瘤和实体瘤治疗的进展、挑战和未来方向。
J Transl Med. 2023 Jul 7;21(1):449. doi: 10.1186/s12967-023-04292-3.
5
IL-27 Improves Prophylactic Protection Provided by a Dead Tumor Cell Vaccine in a Mouse Melanoma Model.白细胞介素-27 增强了死肿瘤细胞疫苗在小鼠黑色素瘤模型中的预防保护作用。
Front Immunol. 2022 Apr 21;13:884827. doi: 10.3389/fimmu.2022.884827. eCollection 2022.
6
CAR/CXCR5-T cell immunotherapy is safe and potentially efficacious in promoting sustained remission of SIV infection.嵌合抗原受体（CAR）/趋化因子受体 5（CXCR5）-T 细胞免疫疗法在促进 SIV 感染的持续缓解方面是安全且有效的。
PLoS Pathog. 2022 Feb 7;18(2):e1009831. doi: 10.1371/journal.ppat.1009831. eCollection 2022 Feb.
7
Advances in Allogeneic Cancer Cell Therapy and Future Perspectives on "Off-the-Shelf" T Cell Therapy Using iPSC Technology and Gene Editing.异体癌细胞治疗的进展和使用 iPSC 技术和基因编辑的“现成”T 细胞治疗的未来展望。
Cells. 2022 Jan 13;11(2):269. doi: 10.3390/cells11020269.
8
Reactive Oxygen Species: Do They Play a Role in Adaptive Immunity?活性氧物种：它们在适应性免疫中发挥作用吗？
Front Immunol. 2021 Nov 22;12:755856. doi: 10.3389/fimmu.2021.755856. eCollection 2021.
9
Enhancing the Efficacy of Tumor Vaccines Based on Immune Evasion Mechanisms.基于免疫逃逸机制提高肿瘤疫苗的疗效
Front Oncol. 2021 Feb 3;10:584367. doi: 10.3389/fonc.2020.584367. eCollection 2020.
10
Telomerase and CD4 T Cell Immunity in Cancer.癌症中的端粒酶与CD4 T细胞免疫
Cancers (Basel). 2020 Jun 25;12(6):1687. doi: 10.3390/cancers12061687.